Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Caroline S. Foo"'
Autor:
Delphine Diana Acar, Wojciech Witkowski, Magdalena Wejda, Ruifang Wei, Tim Desmet, Bert Schepens, Sieglinde De Cae, Koen Sedeyn, Hannah Eeckhaut, Daria Fijalkowska, Kenny Roose, Sandrine Vanmarcke, Anne Poupon, Dirk Jochmans, Xin Zhang, Rana Abdelnabi, Caroline S. Foo, Birgit Weynand, Dirk Reiter, Nico Callewaert, Han Remaut, Johan Neyts, Xavier Saelens, Sarah Gerlo, Linos Vandekerckhove
Publikováno v:
EBioMedicine, Vol 100, Iss , Pp 104960- (2024)
Summary: Background: SARS-CoV-2-neutralizing antibodies (nABs) showed great promise in the early phases of the COVID-19 pandemic. The emergence of resistant strains, however, quickly rendered the majority of clinically approved nABs ineffective. This
Externí odkaz:
https://doaj.org/article/d61b439c0eca42cfae0b6e3405d320a1
Autor:
Sapna Sharma, Thomas Vercruysse, Lorena Sanchez-Felipe, Winnie Kerstens, Madina Rasulova, Lindsey Bervoets, Carolien De Keyzer, Rana Abdelnabi, Caroline S. Foo, Viktor Lemmens, Dominique Van Looveren, Piet Maes, Guy Baele, Birgit Weynand, Philippe Lemey, Johan Neyts, Hendrik Jan Thibaut, Kai Dallmeier
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
Currently licensed COVID-19 vaccines are based on antigen sequences of early SARS-CoV-2 isolates, despite the prevalence of variants of concerns escaping vaccine-mediated protection. Using their updated yellow fever 17D vectored candidate, here, auth
Externí odkaz:
https://doaj.org/article/4924ff2c0d8d4311b6386793aa74eaa2
Autor:
Rana Abdelnabi, Caroline S. Foo, Dirk Jochmans, Laura Vangeel, Steven De Jonghe, Patrick Augustijns, Raf Mols, Birgit Weynand, Thanaporn Wattanakul, Richard M. Hoglund, Joel Tarning, Charles E. Mowbray, Peter Sjö, Fanny Escudié, Ivan Scandale, Eric Chatelain, Johan Neyts
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
There is an urgent need for anti-virals targeting SARS-CoV-2. One of the most promising viral targets is the main protease of SARS-CoV-2, which is essential for viral replication and has no human analogue. Here, Abdelnabi et al. show that one of the
Externí odkaz:
https://doaj.org/article/8a988a1b7f644a20bb1a138315f14db0
Autor:
Rana Abdelnabi, Caroline S. Foo, Suzanne J.F. Kaptein, Xin Zhang, Thuc Nguyen Dan Do, Lana Langendries, Laura Vangeel, Judith Breuer, Juanita Pang, Rachel Williams, Valentijn Vergote, Elisabeth Heylen, Pieter Leyssen, Kai Dallmeier, Lotte Coelmont, Arnab K. Chatterjee, Raf Mols, Patrick Augustijns, Steven De Jonghe, Dirk Jochmans, Birgit Weynand, Johan Neyts
Publikováno v:
EBioMedicine, Vol 72, Iss , Pp 103595- (2021)
Background: Favipiravir and Molnupiravir, orally available antivirals, have been reported to exert antiviral activity against SARS-CoV-2. First efficacy data have been recently reported in COVID-19 patients. Methods: We here report on the combined an
Externí odkaz:
https://doaj.org/article/2e32a0a4a1b54255ac1c5d554b84392d
Autor:
Frauke Assmus, Jean-Sélim Driouich, Rana Abdelnabi, Laura Vangeel, Franck Touret, Ayorinde Adehin, Palang Chotsiri, Maxime Cochin, Caroline S. Foo, Dirk Jochmans, Seungtaek Kim, Léa Luciani, Grégory Moureau, Soonju Park, Paul-Rémi Pétit, David Shum, Thanaporn Wattanakul, Birgit Weynand, Laurent Fraisse, Jean-Robert Ioset, Charles E. Mowbray, Andrew Owen, Richard M. Hoglund, Joel Tarning, Xavier de Lamballerie, Antoine Nougairède, Johan Neyts, Peter Sjö, Fanny Escudié, Ivan Scandale, Eric Chatelain
Publikováno v:
Microorganisms, Vol 10, Iss 8, p 1639 (2022)
In the absence of drugs to treat or prevent COVID-19, drug repurposing can be a valuable strategy. Despite a substantial number of clinical trials, drug repurposing did not deliver on its promise. While success was observed with some repurposed drugs
Externí odkaz:
https://doaj.org/article/a9ef2617e75845fa98746d7ddae47ef7
Autor:
Rana Abdelnabi, Robbert Boudewijns, Caroline S. Foo, Laura Seldeslachts, Lorena Sanchez-Felipe, Xin Zhang, Leen Delang, Piet Maes, Suzanne J.F. Kaptein, Birgit Weynand, Greetje Vande Velde, Johan Neyts, Kai Dallmeier
Publikováno v:
EBioMedicine, Vol 68, Iss , Pp 103403- (2021)
Background: Within one year after its emergence, more than 108 million people acquired SARS-CoV-2 and almost 2·4 million succumbed to COVID-19. New SARS-CoV-2 variants of concern (VoC) are emerging all over the world, with the threat of being more r
Externí odkaz:
https://doaj.org/article/ee564667283f4a5b96d422846fde7095
Autor:
Caroline S. Foo, Rana Abdelnabi, Laura Vangeel, Steven De Jonghe, Dirk Jochmans, Birgit Weynand, Johan Neyts
Publikováno v:
Microorganisms, Vol 10, Iss 3, p 633 (2022)
Ivermectin, an FDA-approved antiparasitic drug, has been reported to have in vitro activity against SARS-CoV-2. Increased off-label use of ivermectin for COVID-19 has been reported. We here assessed the effect of ivermectin in Syrian hamsters infecte
Externí odkaz:
https://doaj.org/article/7eaf70499a3c4e72991303e2bc56dc81
Autor:
Caroline S. Foo, Andréanne Lupien, Maryline Kienle, Anthony Vocat, Andrej Benjak, Raphael Sommer, Dirk A. Lamprecht, Adrie J. C. Steyn, Kevin Pethe, Jérémie Piton, Karl-Heinz Altmann, Stewart T. Cole
Publikováno v:
mBio, Vol 9, Iss 5 (2018)
ABSTRACT New drugs are needed to control the current tuberculosis (TB) pandemic caused by infection with Mycobacterium tuberculosis. We report here on our work with AX-35, an arylvinylpiperazine amide, and four related analogs, which are potent antit
Externí odkaz:
https://doaj.org/article/adb9ac67e2c14c6b855d0f2b8719a48c
Autor:
Craig Fenwick, Priscilla Turelli, Dongchun Ni, Laurent Perez, Kelvin Lau, Cécile Herate, Romain Marlin, Erica Lana, Céline Pellaton, Charlène Raclot, Line Esteves-Leuenberger, Jérémy Campos, Alex Farina, Flurin Fiscalini, Nathalie Dereuddre-Bosquet, Francis Relouzat, Rana Abdelnabi, Caroline S. Foo, Johan Neyts, Pieter Leyssen, Yves Lévy, Florence Pojer, Henning Stahlberg, Roger LeGrand, Didier Trono, Giuseppe Pantaleo
Publikováno v:
Nature Microbiology
The SARS-CoV-2 Omicron variant has very high levels of transmission, is resistant to neutralization by authorized therapeutic human monoclonal antibodies (mAb) and is less sensitive to vaccine-mediated immunity. To provide additional therapies agains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aa2d8d308478607f5a9bccdf91a9cc8
https://lirias.kuleuven.be/handle/20.500.12942/701230
https://lirias.kuleuven.be/handle/20.500.12942/701230
Autor:
Rana Abdelnabi, Caroline S. Foo, Suzanne J. F. Kaptein, Robbert Boudewijns, Laura Vangeel, Steven De Jonghe, Dirk Jochmans, Birgit Weynand, Johan Neyts
Publikováno v:
Journal of Virology. 96
Ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lacks the intrinsic ability to bind to the mouse ACE2 receptor, and therefore establishment of SARS-CoV-2 mouse models has been limited to the use of mouse-adapted viruses or gene